The effects of varying the strength of bupivacaine used in epidurals for the relief of labour pain was examined. The trial randomly allocated sixty women in the first stage of labour to one of three groups. All women were of ASA status 1 or 2 and had uncomplicated pregnancies. Subjects in each group received pethidine 25 mg in 10 ml of either 0.125%, 0.1875%, or 0.25% bupivacaine. Pain scores for each patient were then assessed over the following thirty minutes. Duration of analgesia and subsequent dose requirements were examined. No difference in pain scores between groups at thirty minutes after injection of the test solutions was found. The 0.25% solution group did however have a more rapid onset of analgesia with the majority of patients in this group achieving their maximum effect between ten and twenty minutes after injection. Duration of analgesia was not prolonged by using the stronger solutions. This study suggests that when epidural pethidine 25 mg is added to local anaesthetic solutions ofbupivacaine, adequate analgesia for the first stage of labour is achieved with the 0.125% bupivacaine solution. The use of stronger solutions of bupivacaine achieves no greater degree of analgesia nor longer duration of action, although the onset of analgesia may be faster with the stronger solutions. Further investigations are needed to determine if 25 mg of pethidine is the best choice of dose to use under these circumstances.
In recent years, much attention has been focused on the use of combined low-dose local anaesthetic and opioid epidurals. This has been especially evident in obstetric anaesthetic practice. For pain relief in labour, epidural opioids alone have been shown to be inadequate, or at best, unreliable. I However, numerous studies 2 . 7 have shown the efficacy of low-dose bupivacaine with fentanyl, 2 sufentanil,3,4 and butorphanol. 5 Pethidine has also been studied in conjunction with low-dose bupivacaine in labour. 8 The apparent advantages of a low-dose bupivacaine and opioid combination are many. For the patient there appears to be a lower incidence of motor blockade, shivering,9 and urinary retention. 8 An increased awareness of their labour and greater patient satisfaction is possible compared with stronger concentrations of bupivacaine alone. 8 less danger with inadvertent placement of the drugs intravascularly or in the subarachnoid space, and there may be a lower incidence of hypotension with the weaker solutions. 10 This study compared the use of epidural pethidine 25 mg when combined with 10 ml of eitherbupivacaine 0.125%, 0.1875% or 0.25%. The aim of the study was to determine if use of the stronger local anaesthetic solutions offered any advantage with regard to efficacy of analgesia, rapidity of onset or duration of action. Maternal and neonatal side-effects associated with the use of epidural opioids were also looked for.
MATERIALS AND METHODS Approval for the trial was obtained from the Gold Coast Hospital Ethics Committee. Sixty women, having given informed written consent, were included in the trial. Subjects were of ASA status 1 or 2, had an uncomplicated obstetric history and were in established first stage oflabour. Women with evidence of fetal distress, allergy to the medications to be used, and those in whom epidural analgesia was contraindicated were excluded.
Epidural insertion was performed by the anaesthetic consultant or registrar on call. Needles were placed at the L2,3 or L3,4 interspaces with the patient in the lateral position (although the sitting position could be used if technical difficulties arose). A 16 gauge Tuohy needle was used and the epidural catheter (Portex) was placed four to six centimentres into the epidural space. Aspiration for CSF and blood was made, and if negative, the test solution was injected. Fetal heart rate, measured by stethoscope or cardiotocograph, and maternal pulse and blood pressure were recorded five minutely for 30 minutes following epidural insertion and thereafter every 15 minutes.
Three groups of 20 patients were studied. Subjects were randomly assigned to their respective group in a double-blind manner.
Group I -These patients received 10 ml of 0.125% bupivacaine plus pethidine 25 mg. This solution was made by diluting 5 ml of 0.25% bupivacaine with 5 ml of epidural pethidine (David Bull laboratories 5 mg/ml).
Group 2 -These patients received 10 ml of 0.1875% bupivacaine plus pethidine 25 mg made by mixing 5 ml of 0.375% bupivacaine and 5 ml of epidural pethidine (5 mg/ml).
Group 3 -These patients received 10 ml of 0.25% bupivacaine and pethidine 25 mg made up of 5 ml of 0.5% bupivacaine and 5 ml of epidural pethidine (5 
Ampoules of 20 ml of 0.25%, 0.375% and 0.5% bupivacaine (Astra) had their labels covered with a removable patch (should rapid decoding be required) and labelled with the numbers 1 through 60. This labelling was allocated in a random fashion. Both patient and doctor were blind to the agent strength used. Epidural pethidine 25 mg was chosen, based upon information from previous published work. 8 Pain scores were measured prior to epidural insertion (time 0) and again at 10 minutes, 20 minutes and 30 minutes after injection of the drugs. These pain scores were assessed using a 100 mm visual analogue scale (VAS)" with the extremes marked 0 representing no pain and I 00 the most severe pain imaginable. Failure to achieve adequate analgesia at 30 minutes, as assessed by the patient, required additional local anaesthetic solution. The anaesthetist was free to choose strength and volume of local anaesthetic for this purpose. Patients who required this extra dose of local anaesthetic were recorded as a failure for the final analysis. Patients who did not achieve analgesia for technical reasons, e.g. inappropriate siting of the epidural, were removed from the trial.
In addition to pain scores, patients' ages, weights, heights, parity, and dilatation at insertion of epidural were recorded. Motor function (Bromage scale)'2 was measured at thirty minutes. No attempt was made to mobilise all women although some women did elect to walk after their epidural. Side-effects such as nausea, pruritus, shivering and cardiovascular instability (defined as a blood pressure drop of 20% compared with pre-epidural values, or an absolute value less than 100 mmHg systolic) were also recorded. It was not possible to standardise pre-epidural fluid management as some women had intravenous fluids prior to epidural insertion and others only when the epidural was requested; no fluid loading was specified in the trial's protocol. Duration of epidural analgesia was defined as the time from insertion until the woman requested further pain relief. When delivery occurred before the analgesia had worn off, no duration was recorded.
Epidural top-ups were performed using the same test solution dose as the original (provided this initial solution had produced adequate analgesia). Both patient and anaesthetist were again blinded to the local anaesthetic strength used. With these topups, measures were made of pain, side-effects and motor function as for the initial dose. Mode of delivery, neonatal Apgar scores at one minute and five minutes, and neonatal weights were recorded.
Results were compared for the three groups using ANOV A for demographic data and pain scores, a Tukey's test was used to further discriminate groups if ANOV A showed that significant differences existed, and Chi-squared analysis was used for frequency data. A P value of 0.05 was considered to be statistically significant.
RESULTS
There were no differences between groups with respect to patient age, weight or height. Table 1 gives the mean values for the three groups (with standard deviation in brackets).
Groups did not differ with respect to degree of dilatation at initial epidural insertion, the average dilatation being 4 (± 2) cm for each group. Patients were mainly primagravida with one multigravid patient in Group I and two each in Groups 2 and 3. Table 2 shows the percentage reduction in pain scores compared with the scores at time zero, at the differing time intervals.
The total number offailures is shown in Table 3 . Initially there were three failures in each group: that is, at 30 minutes after the test solution was given, three women in each group felt they had not obtained adequate analgesia and requested further pain relief.
Provided the initial test solutions gave adequate analgesia the study protocol required that subsequent doses, when used, be of the same volume and composition as the original solutions.
The reasoning behind this was to try to analyse whether the weaker solutions could be reliably used throughout the first stage oflabour and not just the earlier phases. Seven Group 2 and nine Group 3 patients had subsequent top-up doses. All patients in these two groups achieved adequate analgesia with these top-up doses. In Group I, 10 patients received a top-up of the 0.125% bupivacaine solution. Of these 10 patients all except two achieved adequate analgesia (Table 3 ). These two Number of patients achieving their final level of analgesia at 10 min. 20 min. and 30 min following epidural injection Group 1 = bupivacaine 0.125% and pethidine 25 mg Group 2 = bupivacaine 0.1875% and pethidine 25 mg Group 3 = bupivacaine 0.25% and pethidine 25 mg patients required stronger local anaesthetic solutions to achieve adequate analgesia. Unfortunately, because of the small number of patients in these top-up groups, we do not believe that a statement concerning differences between groups could be made.
Time to maximum onset of analgesia was measured and these results are presented in Table 4 .
At 20 minutes after injection, 16 out of 17 patients in Group 3 had achieved their maximal level of analgesia, compared with 10 out of 17 in Group I and 2 out of 17 in Group 2. This result is significant at P < 0.05 level betwen Group 3 and Groups I and 2. Table 5 shows duration of effect. There were no differences in duration of effective analgesia between groups.
There were no differences between groups in degree of motor blockade as assessed using the Bromage scale (Table 6) ; two patients in Group 1 and three each in Groups 2 and 3 had a motor block which prevented normal knee flexion (Bromage scale 1) and thus would not have been safe to mobilise. All other subjects were able to completely flex feet and knees. Patients requiring stronger local anaesthetic solution top-ups are not included in this analysis.
Nausea and vomiting occurred in three patients in Group I and four patients in Group 3. Cardiovascular instability occurred in two patients in Group 2 only, both of whom were adequately treated with intravenous fluids alone. No respiratory depression or pruritus was noted in any patient.
The mode of delivery (Table 7) was assessed for subjects who received the test solutions only. Those patients who required stronger local anaesthetic solutions to achieve adequate analgesia were not included in this analysis. There were no differences between groups. As the aim of the study was to look at only the first stage oflabour, the local anaesthetic requirements for caesarian section and for forceps delivery are not included in this paper nor in any of the calculations. Table 8 gives neonatal outcomes for all women in the trial, including those who received stronger local anaesthetic solutions.
DISCUSSION
Assessment of satisfaction with analgesia is difficult in the obstetric population. Brownridge 8 has shown that pain scores are not in themselves necessarily the best indicator of patient satisfaction with epidural analgesia. In this study we attempted only to assess the adequacy of analgesia with epidurals and not the overall patient satisfaction with the technique. In assessing this analgesia we used both visual analogue pain scores and then at 20 20 20 30 minutes after epidural injection asked patients if they were satisfied with the extent of analgesia achieved with the epidural, or if they felt that extra local anaesthetic should be administered. Three patients in each group were dissatisfied with the degree of analgesia achieved after 30 minutes and requested further local anaesthetic. All of these patients achieved satisfactory analgesia when extra local anaesthetic was added. It thus appears that the combination of 25 mg of pethidine when added to 10 ml of either 0.125%, 0.1875% or 0.25% bupivacaine provides adequate analgesia for the first stage oflabour in the majority of patients. Use of the stronger solutions, 0.1875% and 0.25% bupivacaine, did not produce any greater benefit when pain scores were compared at 30 minutes. There was however a significantly more rapid onset of analgesia associated with the use of the 0.25% solution where the maximal effect was achieved between 10 and 20 minutes after injection, compared with the other two solutions which required 20 to 30 minutes to achieve their maximal effect. This differed from Brownridge's series which found satisfactory analgesia with the 0.125% solution was achieved within 10 minutes. 8 Duration of analgesic effect was not statistically different between groups, with a mean duration ranging from 100 to 115 minutes. Expected duration of action should not therefore influence the anaesthetist's choice of solution.
Side-effects were minimal in each group. Even with the stronger local anaesthetic solutions no difference in side-effects could be shown. The incidence of motor block in each group was extremely low, but even in Group 1, two patients were found to have a motor block sufficient to prevent them fully flexing their knees. Hence, although most patients using these solutions should be able to ambulate if desired, even use of the 0.125% bupivacaine solution does not guarantee motor strength adequate to walk. Testing of motor strength and assistance must, therefore, be available prior to mobilising. The lack of significant side-effects in all three groups, in Anaesthesia and Intensive Care, Vol. 20, No. 2, May, 1992 particular the haemodynamic stability, was reassuring.
Outcomes assessed by Apgar scores did not show any difference between groups. Neurobehavioural studies were not performed on babies, but other studies in which epidural opioids have been used have not shown any significant effect from their use. 7 ,8 Furthermore, Brownridge found that pethidine levels at delivery were within the safety range using the same dose of opioids as we used. 8 No baby in our study required naloxone or extensive resuscitation at birth.
Our study set out to determine the optimal dose ofbupivacaine to use when combined with epidural pethidine 25 mg. There appears to be little advantage in using a dose of bupivacaine greater than 10 ml of 0.125%. The stronger dose group (0.25%) had a more rapid onset, but at 30 minutes after injection, no significant differences between groups were evident. Duration of analgesia is not lengthened by using the stronger solutions. Further research is needed to determine the optimal dose of pethidine to use in combination with low-dose local anaesthetics.
In conclusion, the use of pethidine 25 mg with 10 ml of either 0.125%, 0.1875% or 0.25% bupivacaine, is both an effective and safe combination for epidural use in the first stage of labour. The 0.25% bupivacaine solution appeared to have a quicker onset of action; however, on the grounds of patient satisfaction with analgesia, it is not possible to distinguish between the 0.125% solution and the stronger solutions (0.1875% and 0.25%). The efficacy, safety and patient satisfaction with these solutions should make all anaesthetists consider the use of low concentration local anaesthetic and opioid combinations in their obstetric practices. It should be understood, however, that the weaker solutions may require 30 minutes to achieve their full effects.
